Rheumatoid arthritis hits women harder — but treatment goals stay the same

Women with rheumatoid arthritis (RA) face a tougher road than their male counterparts — higher disease activity, worse treatment responses, and faster escalation to advanced therapies — yet the clinical playbook remains largely the same for both sexes. That was the key message from rheumatology experts at the 59th Argentine Congress of Rheumatology, where specialists highlighted growing evidence of sex-based differences in RA while stressing that remission remains the universal treatment goal.

The biological reasons behind these disparities are becoming clearer. Estrogens can weaken immune self-tolerance and alter cytokine production, while androgens tend to suppress pro-inflammatory signals like IL-1, IL-6, and TNF-alpha. Genetics may also play a role — the X chromosome carries over 70 microRNAs compared to just two on the Y chromosome, potentially shaping distinct immune responses between sexes.

Key Takeaways:

• Women show higher baseline disease activity and smaller improvements in DAS44/DAS28 scores compared to men
• In one cohort, 6% of women had already reached third-line treatment at 24 months vs. only 1% of men
• Women starting TNF-alpha inhibitors showed smaller reductions in DAS28, CRP, and swollen joint counts at 12 months
• Clinical trials rarely differentiate by sex, leaving a gap in evidence-based, sex-specific guidance

Why it matters: Despite clear biological and clinical differences, RA management guidelines don't yet account for sex. Experts say clinicians should monitor women more vigilantly, adjust treatment more proactively, and factor in sex-specific considerations — even as the research catches up.